Hematologist @MayoClinic. Hematology/Oncology ‘18 | Internal Medicine ‘15 @MayoClinic. M.D. ad2009 @UFCSPA. Opinions are my own.

Joined November 2009
Research featured at #ASCO26 includes findings that wearable devices may help detect early warning signs of cytokine release syndrome, as well as studies using deep learning to understand the tumor microenvironment in colon cancer. #ASCO26
1
2
4
682
Jonas Paludo retweeted
More efficient healthcare resource utilization can help #CART centers treat more patients. Find out from @jonaspaludo #Tandem2026 how @MayoClinic is using #AI to analyze evolving clinical data to predict onset & severity of #CRS tandem.virtual-meeting.org/p…
1
10
404
Jonas Paludo retweeted
Great question by @DrJasonWestin #SOHO2025 #lymsm session: when will #AI Machine Learning models be used in real time in the clinic? @jonaspaludo @MayoCancerCare the time is now.
5
22
1,001
Jonas Paludo retweeted
Come talk to @Jacob_Shreve_MD tonight #EHA25 poster session to learn how we are using AI to predict CRS long before the first symptom. Earlier prediction=earlier planning & opportunity for risk adapted management. Key to expand access to #CART #BsAb @MayoCancerCare @jonaspaludo
2
6
1
34
2,716
Jonas Paludo retweeted
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell #Lymphoma buff.ly/35DAdE7 In a randomized phase III trial of 598 patients aged ≥65 with previously untreated mantle cell lymphoma (MCL), adding acalabrutinib to bendamustine-rituximab significantly prolonged progression-free survival (66.4 vs. 49.6 months; HR 0.73, P = .016) compared to placebo, with benefits observed across all subgroups, including those with high-risk disease. The combination yielded higher overall and complete response rates (91.0%/66.6% vs. 88.0%/53.5%), though overall survival did not significantly differ between arms. Grade ≥3 adverse events were comparable (88.9% vs. 88.2%). Suggesting that the addition of acalabrutinib provides meaningful clinical benefit with manageable toxicity in first-line MCL treatment. @michaelwangmd @jonaspaludo @chanyooncheah @rule_simon
1
3
7
1,731
Updated #Myeloma Paper of the Day: Depth of response from fixed-duration treatment (i.e. major response @ 6 months) is associated with superior survival (PFS & OS) in #Waldenstrom macroglobulinemia: pubmed.ncbi.nlm.nih.gov/4006…. #mmsm
4
1
10
2,026
Congratulations @jonaspaludo for this excellent collaborative effort! Rational and validated early clinical endpoints are critical in rare diseases like WM.
Updated #Myeloma Paper of the Day: Depth of response from fixed-duration treatment (i.e. major response @ 6 months) is associated with superior survival (PFS & OS) in #Waldenstrom macroglobulinemia: pubmed.ncbi.nlm.nih.gov/4006…. #mmsm
2
3
840
Congratulations to everyone who matched! We are so excited to welcome our new addition to the fellowship family 🎉🎉🎉 #fellowship #match2024 #HemOnc
1
8
1
68
7,965
Thrilled to see our work on IgM gammopathies featured in Dr. Barwick’s insightful commentary in Blood! Excited for the future of research in this field! @KLChohan @JithmaA @pattymondello @MayoClinic @BloodJournal Dr. Stephen Ansell, Dr. Surendra Dasari ashpublications.org/blood/ar…
1
7
29
1,398
#ASCO23 abstract1533 suggests that hospital-based outpatient setting is feasible and safe for administering and monitoring CAR-T #TCellRx and bispecific TCE therapies. #mmsm #lymsm @Radhika_Bansl @YiLinMDPhD @jonaspaludo mayocl.in/43mnCDn
5
1
18
6,768
Check out abstract 1533 @ASCO #ASCO2023 for Teclistamab infusions in the outpatient setting with use of remote patient monitoring. @larissabrunaldi @YiLinMDPhD @jonaspaludo 👉23pt =155 infusions = 98% administered outpt (80% NEVER ADMITTED) ##HCSM #MedEd #mmsm #DigitalHealth
#ASCO23 abstract1533 suggests that hospital-based outpatient setting is feasible and safe for administering and monitoring CAR-T #TCellRx and bispecific TCE therapies. #mmsm #lymsm @Radhika_Bansl @YiLinMDPhD @jonaspaludo mayocl.in/43mnCDn
8
1
20
4,452
🚨 @ASCO Abstract 1535: Many people with #cancer will experience a neutropenic fever over the course of their care journey. Traditionally, this requires a lengthy hospital stay while awaiting count recovery. This decreases patients’ quality of life, increases the cost of care for patients and health systems, forces delays in care, and limits the quantity of time patients are able to spend outside the hospital doing the things they love. At @MayoClinic @MayoCancerCare, we built a program to change that. Introducing the “DEFeNDR” program - an innovative remote patient monitoring (#RPM) system designed to facilitate safe and effective outpatient management and give time back to our patients. And that’s just the beginning. I am beyond proud to present the first glimpse of this work at #ASCO23. We show that patients participating in the program spend less time in the hospital. In addition, when readmitted, patients using the program experience shorter length of stay and lower rates of intensive care unit utilization. Come learn more at the poster session on Monday, June 5. meetings.asco.org/abstracts-… #digitalhealth @HemOncFellows @OncoAlert Thanks to so many mentors, colleagues, and collaborators including (on Twitter): @jonaspaludo @khera_nandita @RozalinaMD @ZYetmar @n_gangat @DrJonTilburt @MayoHemeOnc @MayoKernScholar
2
7
3
32
5,809
We are celebrating Bob Kyle’s 95th Birthday today. @MayoClinic @MayoMyeloma @MayoCancerCare Picture taken today at The Foundation House at Mayo Clinic. 1/
20
19
6
260
38,856
Jonas Paludo retweeted
📣Our latest @TheIACH Webinar: Telemedicine in hematology: where do we stand? Now available on-demand! View the full library for FREE⬇️ clinical-hematology.org/vide… @Mohty_EBMT @albertomussetti @jonaspaludo
6
1
10
1,617
Jonas Paludo retweeted
We are using remote monitoring to improve compliance for safety monitoring and patient experience. This also increase our capacity, thereby pt access to novel treatment #CART and #BiSAb @MayoCancerCare @DrTufiaHaddad @jonaspaludo
Dynamic care models have shown promise for producing better outcomes and more positive patient experiences. Learn about the increasing relevance of leveraging remote patient monitoring systems, touching nearly every medical specialty: mayocl.in/3yjyCDS @MayoPlatform
6
20
2,507
Introducing our incoming Chief Fellows - @RichGodby and Caleb Smith!
3
4
1
45
5,159